- Home
- Equipment
- latamerica
- clinics case study
Refine by
Locations
- Latin America
- Antigua & Barbuda
- Argentina
- Aruba
- Bahamas
- Barbados
- Belize
- Bolivia
- Brazil
- Cayman Islands
- Chile
- Colombia
- Costa Rica
- Cuba
- Dominica
- Dominican Republic
- Ecuador
- El Salvador
- Grenada
- Guatemala
- Guyana
- Haiti
- Honduras
- Jamaica
- Mexico
- Netherlands Antilles
- Nicaragua
- Panama
- Paraguay
- Peru
- Puerto Rico
- St. Kitts & Nevis
- St. Lucia
- St. Vincent & The Grenadines
- Suriname
- Trinidad
- Uruguay
- Venezuela
Novel Moa Clinics Case Study Equipment & Supplies In Latin America
1 equipment items found
by:Relmada Therapeutics, Inc. based inCoral Gables, FLORIDA (USA)
Novel MOA: REL-1017 works as an NMDAR channel blocker with preferential activity at hyperactive GluN1-GluN2D channels. REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major Depressive Disorder (MDD). REL-1017 works with a MOA markedly different from standard serotoninergic ...